<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384914</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19117</org_study_id>
    <nct_id>NCT03384914</nct_id>
  </id_info>
  <brief_title>Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer</brief_title>
  <official_title>A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of each study vaccine and to&#xD;
      evaluate the effect on the time to disease recurrence (assessed by disease free survival).&#xD;
&#xD;
      Participants will be assigned to receive one of two study vaccines (DC1 study vaccine vs.&#xD;
      WOKVAC). The study vaccine will be administered in two phases: a study vaccination phase and&#xD;
      a booster phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of the study will be 6 years (4 years of patient enrollment and 2&#xD;
      additional years of clinical follow-up). Assessment for disease recurrence and survival will&#xD;
      be conducted every 6 months (with a phone call/secure email, medical records or follow up&#xD;
      visit) from the end of treatment for a total of 2 years, until the completion of the trial or&#xD;
      until documented disease recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>The primary immunogenicity outcome for both arms of this trial will be the summation of spots (ELISPOT) for 6 distinct peptides and reported as total SFC/10^6 cells. A value &gt;150 defines an immune response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Clinical activity is characterized by disease-free survival (DFS), defined as the time from start of treatment to documented recurrence (any breast event), death due to any cause or last patient contact that documents recurrence-free status (i.e., a clinic or scan date).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Breast Cancer, Male</condition>
  <condition>Breast Cancer Stage I</condition>
  <condition>Breast Cancer Stage II</condition>
  <condition>Breast Cancer Stage III</condition>
  <condition>Residual Disease</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>HER2 Positive Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Dendritic Cell (DC1) Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The vaccine will be administered in two phases: a vaccination phase and a booster phase.&#xD;
Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pUMVC3-IGFBP2-HER2-IGF1R (WOKVAC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The vaccine will be administered in two phases: a vaccination phase and a booster phase.&#xD;
Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC1 Vaccine</intervention_name>
    <description>Vaccination Phase: DC1 vaccine will be administered weekly via intranodal injection in weeks 1 to 6 (window 8-21days between vaccines).&#xD;
Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month).</description>
    <arm_group_label>Dendritic Cell (DC1) Vaccine</arm_group_label>
    <other_name>Immunotherapy</other_name>
    <other_name>Dendritic Cell Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>WOKVAC Vaccine</intervention_name>
    <description>Vaccination Phase: WOKVAC vaccine will be administered via intradermal injection on weeks 1, 4 and 7 (window +21 days).&#xD;
Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month).</description>
    <arm_group_label>pUMVC3-IGFBP2-HER2-IGF1R (WOKVAC)</arm_group_label>
    <other_name>Immunotherapy</other_name>
    <other_name>pUMVC3-IGFBP2-HER2-IGF1R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical stage I-III HER2 positive breast cancer treated with neoadjuvant chemotherapy&#xD;
             including HER-2 directed treatment for at least 12 weeks.&#xD;
&#xD;
          -  Residual invasive carcinoma in the breast or axillary nodes in the final pathology&#xD;
             from resected tumor following neoadjuvant chemotherapy.&#xD;
&#xD;
          -  Completed last cycle of cytotoxic chemotherapy (excluding ado-trastuzumab emtansine&#xD;
             [T-DM1]) or radiation &gt; 30 days with resolution of all acute toxic effects of prior&#xD;
             therapy to grade ≤ 2 (except alopecia)&#xD;
&#xD;
          -  Currently on HER-2 targeted therapy (eg; trastuzumab +/- pertuzumab or T-DM1) per&#xD;
             standard of care or has completed HER-2 targeted therapy less than 6 months ago&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Eastern Cooperative Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          -  Must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,000/ μL&#xD;
&#xD;
               -  Platelets ≥ 75,000/ μL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), except&#xD;
                  patients with Gilbert's syndrome in whom total bilirubin must be &lt;3.0 mg/dL&#xD;
&#xD;
               -  AST/ALT ≤ 3 x institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  Hemoglobin A1C &lt;6.5%&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) above institutional lower limit of normal&#xD;
             (by echocardiogram or MUGA scan within 90 days of registration).&#xD;
&#xD;
          -  Females of child-bearing potential must agree to use dual methods of contraception and&#xD;
             have a negative serum pregnancy test at screening, and males must use an effective&#xD;
             barrier method of contraception if sexually active with a female of child-bearing&#xD;
             potential. For both male and female participants, effective methods of contraception&#xD;
             must be used throughout the study and for three months following the last dose.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
             prior to initiation of any screening or study-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, congenital prolonged QT syndrome, symptomatic congestive heart failure,&#xD;
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements.&#xD;
&#xD;
          -  Uncontrolled autoimmune disease requiring active systemic treatment.&#xD;
&#xD;
          -  Known hypersensitivity reaction to the Granulocyte-macrophage colony stimulating&#xD;
             factor (GM-CSF) adjuvant; any known contraindication to GM-CSF.&#xD;
&#xD;
          -  Pregnant or breast feeding.&#xD;
&#xD;
          -  Known HIV-positive.&#xD;
&#xD;
          -  Known current or a history of hepatitis B or C virus, including chronic and dormant&#xD;
             states, unless disease has been treated and confirmed cleared.&#xD;
&#xD;
          -  Major surgery within 4 weeks of initiation of study drug.&#xD;
&#xD;
          -  Current extended use of immunosuppressive agents or systemic corticosteroids. Topical,&#xD;
             ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal&#xD;
             systemic absorption) are allowed. A brief course of corticosteroids for prophylaxis&#xD;
             (eg., for contrast dye allergy) or for treatment of non-autoimmune conditions (eg.,&#xD;
             delayed-type hypersensitivity reaction caused by a contact allergen) is permitted.&#xD;
&#xD;
          -  Potential participant is currently on active treatment in any other clinical protocol&#xD;
             or investigational trial that involves administration of experimental therapy and/or&#xD;
             therapeutic devices, or investigational drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo S. Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna Hogue</last_name>
      <phone>813-745-8304</phone>
      <email>Deanna.Hogue@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Hyo S. Han, M.D.</last_name>
      <phone>813-745-4933</phone>
      <email>hyo.han@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Hyo S. Han, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian J. Czerniecki, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory - Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>McKenzie Duncan</last_name>
      <phone>404-778-4824</phone>
      <email>mtdunca@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Keerthi Gogineni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University - Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Versie L Barnes</last_name>
      <phone>317-278-3127</phone>
      <email>barnesv@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Carla Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Bicomong</last_name>
      <phone>732-235-9567</phone>
      <email>MB1444@cinj.rutgers.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yue J Wang, MD, PhD</last_name>
      <phone>732-235-8995</phone>
      <email>yw670@cinj.rutgers.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Kowzun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Williams</last_name>
      <phone>716-845-8891</phone>
      <email>Lauren.Williams@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Shipra Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University - Arthur G James Cancer Hospital &amp; Richard J Solove Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Wyse</last_name>
      <phone>614-685-0380</phone>
      <email>Meghan.wyse@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Wesolowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington, Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>(Mary) Nora S. Disis, M.D.</last_name>
      <phone>206-616-1823</phone>
      <email>ndisis@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Mary (Nora) Disis, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinical-trials-research/</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2017</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>axillary nodes</keyword>
  <keyword>HER-2 directed treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

